Keywords: دنوزوماب، دنوسوماب; Percutaneous vertebroplasty; Pathological fractures; Denosumab; RANK ligand antibody; Spinal metastasis; Osteoporosis
مقالات ISI دنوزوماب، دنوسوماب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: دنوزوماب، دنوسوماب; Metastatic castration-resistant prostate cancer; Consensus; Radium 223 dichloride; Abiraterone; Enzalutamide; Docetaxel; Circulating tumour cells; Sipuleucel-T; Cabazitaxel; Denosumab;
Keywords: دنوزوماب، دنوسوماب; cathepsin K; odanacatib; sclerostin; romosozumab; blosozumab; denosumab; teriparatide; PTHrP; osteoporosis; fractures
Keywords: دنوزوماب، دنوسوماب; Prostate cancer; Castration-resistance; Sipuleucel-T; Cabazitaxel; Abiraterone; Enzalutamide; Denosumab
Keywords: دنوزوماب، دنوسوماب; osteoporosis; men; therapy; bisphosphonates; denosumab; teriparatide; strontium ranelate; testosterone; odanacatib romosozumab
Keywords: دنوزوماب، دنوسوماب; Multiple myeloma; RANKL; Bisphosphonates; Zoledronic acid; Denosumab;
Keywords: دنوزوماب، دنوسوماب; Bisphosphonate; Denosumab; Osteonecrosis of the jaw; Zoledronate;
Keywords: دنوزوماب، دنوسوماب; Castration resistant prostate cancer; CRPC; Elderly; Abiraterone; Cabazitaxel; Sipuleucel-T; Enzalutamide; Alpharadin; Denosumab;
Keywords: دنوزوماب، دنوسوماب; Cynomolgus monkeys; Pre-postnatal toxicity; Embryofetal toxicity; Denosumab; Reproductive toxicity;
Keywords: دنوزوماب، دنوسوماب; Denosumab; Bisphosphonates; Post-menopausal osteoporosis; Bone mineral density; C-telopeptide
Keywords: دنوزوماب، دنوسوماب; RANKL; Breast; Cancer; Progesterone; Progestin; Denosumab
Keywords: دنوزوماب، دنوسوماب; Osteoporosis; Antibody; Sclerostin; Dickkopf-1; Denosumab
Denosumab significantly improves lumbar spine bone mineral density more in treatment-naïve than in long-term bisphosphonate-treated patients
Keywords: دنوزوماب، دنوسوماب; Bisphosphonate; Bone mineral density; Denosumab; Long-term bisphosphonate therapy; Osteoporosis;
Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone
Keywords: دنوزوماب، دنوسوماب; Giant cell tumor of bone; H3F3A; Mutation; Immunohistochemistry; Denosumab;
The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review
Keywords: دنوزوماب، دنوسوماب; Denosumab; RANK; RANKL; Anti-tumor; Immunity; Breast cancer;
Dénosumab associé aux bDMARDÂ : efficacité sur la progression radiographique dans la polyarthrite rhumatoïde
Keywords: دنوزوماب، دنوسوماب; Dénosumab; Agent biologique; Polyarthrite rhumatoïde; Progression radiographique;
Preoperative Cytoreduction of Clival Giant Cell Tumor: An Effective Replication of the Systemic Modality in the Skull Base
Keywords: دنوزوماب، دنوسوماب; Denosumab; Giant cell tumors; Skull base; GCT; Giant cell tumor; RANK; Receptor activator of nuclear factor-κB; RANKL; Receptor activator of nuclear factor-κB ligand;
Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial
Keywords: دنوزوماب، دنوسوماب; Denosumab; RANKL; Giant cell tumor of bone; Neoadjuvant therapy;
Effects of single or combination therapy of teriparatide and anti-RANKL monoclonal antibody on bone defect regeneration in mice
Keywords: دنوزوماب، دنوسوماب; Ab group; group receiving anti-RANKL Ab; anti-RANKL Ab; anti-murine RANKL antibody; BFR/BS; bone formation rate per bone surface; BFR/TV; bone formation rate per tissue volume; BMD; bone mineral density; BV/TV; bone volume fraction; CNT group; group recei
Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series
Keywords: دنوزوماب، دنوسوماب; Denosumab; Jaw osteonecrosis; MRONJ; ARONJ; DRONJ; ONJ;
A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma
Keywords: دنوزوماب، دنوسوماب; Sorafenib; Advanced osteosarcoma; Denosumab; Everolimus; Novel therapy; Second line; RANKL; Tyrosine kinase; Nexavar; MTORC; Italian Sarcoma Group; Primary bone cancer; MAPK; ERK; Temsirolimus; Bevacizumab;
Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
Keywords: دنوزوماب، دنوسوماب; Denosumab; Discontinuation; Fracture; Osteoporosis; Rheumatoid arthritis;
Update MRONJ and perspectives of its treatment
Keywords: دنوزوماب، دنوسوماب; Bisphosphonates; Osteonecrosis of the jaw; Denosumab; ARONJ;
Case reportCyberknife stereotactic radiosurgery and denosumab for giant cell tumour of the skull base: Case report
Keywords: دنوزوماب، دنوسوماب; Cyberknife; Stereotactic radiosurgery; Denosumab; Giant cell tumour; Skull base;
Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases
Keywords: دنوزوماب، دنوسوماب; Denosumab; Recurrence; Giant cell tumor;
Effects of Teriparatide, Denosumab, or Both on Spine Trabecular Microarchitecture in DATA-Switch: a Randomized Controlled Trial
Keywords: دنوزوماب، دنوسوماب; Denosumab; osteoporosis; teriparatide;
Full Length ArticleRelationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study
Keywords: دنوزوماب، دنوسوماب; Osteoporosis; Bone resorption; Bone turnover markers; Denosumab; Teriparatide; Bone formation;
Role of microbiological culture and polymerase chain reaction (PCR) of actinomyces in medication-related osteonecrosis of the jaw (MRONJ)
Keywords: دنوزوماب، دنوسوماب; MRONJ; PCR; Microbiology; Bisphosphonates; Denosumab; Actinomyces;
Original ResearchDenosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
Keywords: دنوزوماب، دنوسوماب; Giant-cell tumour of the bone; Denosumab; Receptor activator of nuclear factor κB ligand; GCTB; ONJ;
Traitements anti-résorptifs pour le traitement et la prévention des métastases osseuses
Keywords: دنوزوماب، دنوسوماب; Métastases osseuses; Ostéolyse maligne; Bisphosphonates; Dénosumab; Bone metastases; Malignant osteolysis; Bisphosphonates; Denosumab;
Prise en charge des lésions osseuses du myélome multiple : quelles particularités ?
Keywords: دنوزوماب، دنوسوماب; Myélome multiple; Ostéolyse maligne; Bisphosphonates; Dénosumab; Chirurgie; Radiothérapie; Vertébroplastie; Multiple myeloma; Malignant osteolysis; Bisphosphonates; Denosumab; Surgery; Radiotherapy; Vertebroplasty;
ReviewGiant cell tumour of bone in the denosumab era
Keywords: دنوزوماب، دنوسوماب; Denosumab; RANK ligand; Giant cell tumour of bone;
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
Keywords: دنوزوماب، دنوسوماب; Breast cancer; Osteoporosis; Endocrine treatment; Fracture; Bisphosphonate; Denosumab;
Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ
Keywords: دنوزوماب، دنوسوماب; Bisphosphonates; denosumab; diagnosis; management; osteonecrosis of the jaw;
Osteoporosis management in patients with breast cancer: EMAS position statement
Keywords: دنوزوماب، دنوسوماب; Breast cancer; Osteoporosis; Fractures; Screening; Aromatase inhibitors; Bisphosphonates; Denosumab; Adjuvant therapy;
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS
Keywords: دنوزوماب، دنوسوماب; Osteoporosis treatment; Denosumab; Discontinuation; Fractures; Position paper;
Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies
Keywords: دنوزوماب، دنوسوماب; Benefits; Bisphosphonate; Denosumab; Fracture; Long-term therapy; Osteoporosis; Risks;
Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement
Keywords: دنوزوماب، دنوسوماب; Bisphosphonates; Alendronate; Risedronate; Zoledronic acid; Denosumab; Drug holiday;
Clinical course and therapeutic outcomes of operatively and non-operatively managed patients with denosumab-related osteonecrosis of the jaw (DRONJ)
Keywords: دنوزوماب، دنوسوماب; Denosumab; Osteonecrosis; Bisphosphonates; Medication-related osteonecrosis of the jaw;
Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics
Keywords: دنوزوماب، دنوسوماب; osteoporois; biochemical markers of bone turnover; BMD; osteoanabolics; parathyroid hormone; antiresorptive therapy; bisphosphonates; denosumab;
Rethinking end-points for bone-targeted therapy in advanced cancer
Keywords: دنوزوماب، دنوسوماب; End-points; Clinical trials; Bone metastases; Bisphosphonates; Denosumab; Solid tumours;
Granulome central à cellules géantes de l'enfant : présentation des différentes options thérapeutiques
Keywords: دنوزوماب، دنوسوماب; Granulome central à cellules géantes; Corticothérapie; Alendronate; Denosumab; Calcitonine; Interferon; Granuloma giant cell; Steroids; Alendronate; Denosumab; Calcitonine; Interferon;
Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial
Keywords: دنوزوماب، دنوسوماب; Bone mineral density; combination therapy; denosumab; postmenopausal osteoporosis; teriparatide;
Septic shock associated with denosumab-related osteonecrosis of the jaw: A case report and literature review
Keywords: دنوزوماب، دنوسوماب; Denosumab; Osteonecrosis; Septic shock
Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients
Keywords: دنوزوماب، دنوسوماب; Denosumab; Osteonecrosis of the jaw; Metastatic bone disease
Response to letter to the editor by Leder et al. regarding commentary “Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics”
Keywords: دنوزوماب، دنوسوماب; Osteoporosis; Parathyroid hormone; Teriparatide; Denosumab; Concurrent therapy;
Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and treatment with denosumab
Keywords: دنوزوماب، دنوسوماب; NOTCH; Bone remodeling; Fractures; Acroosteolysis; Denosumab; Splenomegaly;
Bone health in the elderly cancer patient: A SIOG position paper
Keywords: دنوزوماب، دنوسوماب; Breast cancer; Prostate cancer; Myeloma; Bone health; Bisphosphonates; Denosumab;
Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics
Keywords: دنوزوماب، دنوسوماب; Denosumab; Zoledronic acid; Bone metastases; Skeletal-related event; Subgroup;
Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone
Keywords: دنوزوماب، دنوسوماب; Giant cell tumour of the bone; Denosumab; Histopathological findings; Radiological effects; Joint preservation